Does nicotinic acid (niacin) lower blood pressure?

被引:32
作者
Bays, H. E. [1 ]
Rader, D. J. [2 ]
机构
[1] Louisville Metab & Atherosclerosis Res Ctr, Louisville, KY 40213 USA
[2] Inst Diabet Obes & Metab, Cardiovasc Metab Unit, Philadelphia, PA USA
关键词
HEALED MYOCARDIAL-INFARCTION; COLESTIPOL-NIACIN; CORONARY ATHEROSCLEROSIS; SECONDARY PREVENTION; METABOLIC SYNDROME; HEART-DISEASE; THERAPY; CHOLESTEROL; EFFICACY; REGRESSION;
D O I
10.1111/j.1742-1241.2008.01934.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nicotinic acid (niacin) is a well-established treatment for dyslipidaemia - an important cardiovascular disease (CVD) risk factor. However, niacin may also reduce blood pressure (BP), which is another important CVD risk factor. This review examines the limited publicly available data on niacin's BP effects. Acute administration of immediate-release niacin may lower BP because of niacin's acute vasodilatory effects. Although not always supported by clinical trial data, the package insert of a prescription, extended-release niacin describes niacin-induced acute hypotension. From a chronic standpoint, larger studies, such as the Coronary Drug Project, suggest that niacin may lower BP when administered over a longer period of time. Post hoc analyses of some of the more recent niacin clinical trials also support a more chronic, dose-dependent, BP-lowering effect of niacin. Because laropiprant [a prostaglandin D-2 (PGD(2)) type 1 (DP1) receptor antagonist] does not attenuate niacin's BP-lowering effects, it is unlikely that any chronic lowering of BP by niacin is due to dilation of dermal vessels through activation of the DP1 receptor by PGD(2.) Further research is warranted to evaluate the extent and mechanisms of niacin's effects on BP.
引用
收藏
页码:151 / 159
页数:9
相关论文
共 48 条
[1]  
*ABB LAB, NIASP TABL NIAC EXT
[2]  
*ABB LAB, ADV NIAC EXT REL LOV
[3]   INFLUENCE OF NICOTINIC ACID ON SERUM CHOLESTEROL IN MAN [J].
ALTSCHUL, R ;
HOFFER, A ;
STEPHEN, JD .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1955, 54 (02) :558-559
[4]  
[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360
[5]  
BAYS H, 2008, AM COLL CARD 57 ANN
[6]  
Bays Harold E, 2008, Expert Rev Cardiovasc Ther, V6, P343, DOI 10.1586/14779072.6.3.343
[7]   CORONARY ANGIOGRAPHIC CHANGES WITH LOVASTATIN THERAPY - THE MONITORED ATHEROSCLEROSIS REGRESSION STUDY (MARS) [J].
BLANKENHORN, DH ;
AZEN, SP ;
KRAMSCH, DM ;
MACK, WJ ;
CASHINHEMPHILL, L ;
HODIS, HN ;
DEBOER, LWV ;
MAHRER, PR ;
MASTELLER, MJ ;
VAILAS, LI ;
ALAUPOVIC, P ;
HIRSCH, LJ .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (10) :969-976
[8]   BENEFICIAL-EFFECTS OF COLESTIPOL-NIACIN THERAPY ON THE COMMON CAROTID-ARTERY - 2-YEAR AND 4-YEAR REDUCTION OF INTIMA-MEDIA THICKNESS MEASURED BY ULTRASOUND [J].
BLANKENHORN, DH ;
SELZER, RH ;
CRAWFORD, DW ;
BARTH, JD ;
LIU, CR ;
LIU, CH ;
MACK, WJ ;
ALAUPOVIC, P .
CIRCULATION, 1993, 88 (01) :20-28
[9]   BENEFICIAL-EFFECTS OF COMBINED COLESTIPOL-NIACIN THERAPY ON CORONARY ATHEROSCLEROSIS AND CORONARY VENOUS BYPASS GRAFTS [J].
BLANKENHORN, DH ;
NESSIM, SA ;
JOHNSON, RL ;
SANMARCO, ME ;
AZEN, SP ;
CASHINHEMPHILL, L .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (23) :3233-3240
[10]   EFFECTS OF COLESTIPOL-NIACIN THERAPY ON HUMAN FEMORAL ATHEROSCLEROSIS [J].
BLANKENHORN, DH ;
AZEN, SP ;
CRAWFORD, DW ;
NESSIM, SA ;
SANMARCO, ME ;
SELZER, RH ;
SHIRCORE, AM ;
WICKHAM, EC .
CIRCULATION, 1991, 83 (02) :438-447